Objective The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …

Purpose Dual bronchodilator therapy with a long-acting muscarinic antagonist (LAMA) and a
long-acting β 2-agonist (LABA) is recommended in the pharmacological management of …

Dual bronchodilation therapy is the cornerstone for the treatment of chronic obstructive
pulmonary disease (COPD)[1]. Combining a long-acting β2 adrenoceptor (β2-AR) agonist …

Background: Chronic obstructive pulmonary disease (COPD) guidelines recommend both
long-acting and dual bronchodilator therapy. It is unclear if there are differences in efficacy …

Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting
muscarinic antagonist [LAMA] plus a long-acting β2-agonist [LABA]) are available for the …

Chronic obstructive pulmonary disease (COPD) represents a significant cause of global
morbidity and mortality, with a substantial economic impact. Recent changes in the Global …

Current guidelines recommend treatment with one or more bronchodilators for chronic
obstructive pulmonary disease (COPD) patients. Combination therapy with long-acting …

Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …

Although pharmacological treatment of COPD is codified in different guidelines and strategy
documents, there is abundant evidence of discrepancy between what they suggest and what …

Despite several long-acting β 2-adrenoceptor agonist (LABA)/long-acting muscarinic
antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved for the treatment …